The University of Notre Dame has been working in the area of precision medicine for more than a decade, but a recent $20 million gift is adding muscle to the effort, creating “a much larger impact than our footprint would ordinarily predict,” says Dr. Paul Bohn. He’s the director of the newly established Berthiaume Institute for Precision Health, made possible by the gift from a family with very little connection to the school—but a firm belief in Notre Dame’s ability to forward biomedicine, while also being “a force for good.”
A key goal for the Berthiaume Institute is to be an engine for translational research, providing the building blocks for startups, Inside Indiana Business reports.
“It’s not just a discovery that makes a new company, but it’s a discovery that’s made in a supportive and nurturing environment with access to the right kinds of resources, such as CEO talent, venture capital and infrastructure to support the work,” says Bohn. “We hope to be a locus for a lot of activity in that realm in the future.”
The university says corporate partners also play an important role in the overall “bioanalytical ecosystem” at Notre Dame. Local and regional partners include Eli Lilly and Co., Corteva Agriscience, Indiana Biosciences Research Institute and AbbVie Inc. in Chicago. Read more.
